<DOC>
	<DOCNO>NCT02106182</DOCNO>
	<brief_summary>The objective study determine safety efficacy silodosin , treatment benign prostatic hyperplasia high selectivity α1A-receptor , patient benign prostatic hyperplasia accompany nocturia .</brief_summary>
	<brief_title>Efficacy Safety Silodosin Nocturia Patients With Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>This study design multi-center , prospective , open-label single-arm study . Subjects willing provide write informed consent enrol screen eligibility criterion . The subject administer investigational product 12 week visit outpatient evaluation safety efficacy baseline ( visit 2 ) 4 week ( visit 3 ) 12 week ( visit 4 ) baseline .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Males least 50 year age , current diagnosis benign prostatic hyperplasia Symptoms nocturia evidence ≥2 episode per night average accord 3day void diary More total 8 point IPSS 3 point QoL Able provide write informed consent comply study procedure PSA level &gt; 10 ng/㎖ ( except patient 4 ng/㎖ &lt; PSA level ≤ 10 ng/㎖ 6 month prior screen identify negative biopsy ) Symptoms postural hypotension Severe renal disorder creatinine clearance ≥ 2.0 mg/dL Severe hepatic disorder AST ALT ≥ 3 x upper limit normal ( ULN ) Severe cardiac disorder development diagnosis vascular disorder ( unstable angina , myocardial infarction , cerebral infarction , cerebral hemorrhage , coronary artery bypass graft , etc ) 6 month prior enrollment Any disorder gastrointestinal system could result altered digestion absorption , history gastrointestinal tract surgery except ecphyadectomy Patients bladder cancer , cystolith urethral stricture Patients neurogenic bladder History acute urinary retention Indwelling catheter self intermittent catheterization Patients pyuria 1 month prior screen History prostatic cancer History prostatic surgery Patients uncontrolled chronic disease Alcoholism sustain drug dependent abuse 1 year prior screen Hypersensitivity α1Areceptor blocker Administration follow drug within accord period prior screen 2 week : Antimuscarinic agent ( Tolterodine , Trospium , Solifenacin , Fesoterodine , Propiverine , Oxybutynin , Flavoxate , etc ) , Anticholinesterase agent ( Neostigmine methylsulfate , etc ) , Cholinergic agonists ( Bethanechol Cl , etc ) , Benign prostatic hyperplasia agent ( Tamsulosin HCl , Prazosin HCl , Terazosin HCl , Doxazosin mesylate , Silodosin , Naftopidil , etc ) , Tricyclic antidepressant ( Amitriptyline , Clomipramine , Dosulepin , Doxepin , Imipramine , Quinupramine , etc ) , 6 month : 5αReductase Inhibitors ( Finasteride , Dutasteride ) Presence condition abnormality opinion investigator would compromise safety patient quality data</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>Nocturia</keyword>
	<keyword>Silodosin</keyword>
	<keyword>Thrupas</keyword>
</DOC>